Therapeutical Class：Aminoglycosides, inhibit protein synthesis by binding to 30S ribosomal subunits

Indication：G(-): E.coli, H. influenzae, Klebsiella, Enterobacter, Pseudomonas, Proteus, Providencia, Serratia, some Acinetobacter; G(+): Staphylococci.

Administraton：IM or IV .

Adults: 15 mg/kg/day in 2-3 divided doses or 15 mg/kg once daily, max: 1.5 g/day. Hospital-acquired pneumonia: 20 mg/kg/day.

Meningitis: 5 mg/kg every 8 hours .

Renal impairment: Ccr>60 ml/min, q8h;

Ccr 40-60 ml/min, q12h;

Ccr 20-40 ml/min, qd;

Ccr <20 ml/min, loading dose, then monitor levels.

Dialysis: 5-7.5 mg/kg every 48-72 hours after hemodialysis, then follow levels.

Adverse Effect：Renal dysfunction (1-10%), hearing abnormalities (1-10%), allergy (rash, etc. <1%),, neurotoxicity arthralgia, drowsiness, dyspnea, eosinophilia, headache, hypotension, nausea, paresthesia, tremor, vomiting.

Pregnancy Risk：DSupply：Aminfec XE “Aminfec”  Inj 250mg/2ml（安炎注射液 生達）＜11055＞